Johnson & Johnson Effective Income Tax Rate Reconciliation, Tax Settlement, Percent
Johnson & Johnson (JNJ) reported Effective Income Tax Rate Reconciliation, Tax Settlement, Percent of 22.00% for the 9-month period ending 2025-09-28, per its 10-Q filed 2025-10-22.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements · last filed 2026-07-23
- Johnson & Johnson effective income tax rate reconciliation, tax settlement, percent for the quarter ending 2025-06-29 was 22.00%.
- Johnson & Johnson effective income tax rate reconciliation, tax settlement, percent for the quarter ending 2025-03-30 was 22.00%, a 0.00% change year-over-year.
- Johnson & Johnson effective income tax rate reconciliation, tax settlement, percent for the quarter ending 2024-03-31 was 22.00%, a 4.35% decline year-over-year.
- Johnson & Johnson effective income tax rate reconciliation, tax settlement, percent for the quarter ending 2023-04-02 was 23.00%.
- Johnson & Johnson effective income tax rate reconciliation, tax settlement, percent for fiscal 2023 was 22.00%.
| Period end | Effective Income Tax Rate Reconciliation, Tax Settlement, Percent 3 month | Effective Income Tax Rate Reconciliation, Tax Settlement, Percent 3 month as first filed | Effective Income Tax Rate Reconciliation, Tax Settlement, Percent 6 month | Effective Income Tax Rate Reconciliation, Tax Settlement, Percent 6 month as first filed | Effective Income Tax Rate Reconciliation, Tax Settlement, Percent 9 month | Effective Income Tax Rate Reconciliation, Tax Settlement, Percent 9 month as first filed | Effective Income Tax Rate Reconciliation, Tax Settlement, Percent 12 month |
|---|---|---|---|---|---|---|---|
| 2025-09-28 | 22.00% 10-Q · filed 2025-10-22 | ||||||
| 2025-06-29 | 22.00% 10-Q · filed 2026-07-23 | 22.00% 10-Q · filed 2025-07-24 | |||||
| 2025-03-30 | 22.00% 10-Q · filed 2026-04-22 | ||||||
| 2024-09-29 | 22.00% 10-Q · filed 2025-10-22 | 23.00% 10-Q · filed 2024-10-23 | |||||
| 2024-06-30 | 22.00% 10-Q · filed 2025-07-24 | 23.00% 10-Q · filed 2024-07-25 | |||||
| 2024-03-31 | 22.00% 10-Q · filed 2025-04-23 | 23.00% 10-Q · filed 2024-05-01 | |||||
| 2023-12-31 | 22.00% 10-K · filed 2026-02-11 | ||||||
| 2023-10-01 | 23.00% 10-Q · filed 2024-10-23 | ||||||
| 2023-07-02 | 23.00% 10-Q · filed 2024-07-25 | ||||||
| 2023-04-02 | 23.00% 10-Q · filed 2024-05-01 | ||||||
| 2019-09-29 | 2.00% 10-Q · filed 2019-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |